semaglutide indian pharmacy India pharma companies develop versions of Wegovy to get in on weight-loss windfall Indian Pharma Majors Line Up

No official maintenance dose protocol exists because the research does not support stepping down

Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

However, direct comparisons require caution because: Trial lengths differed Dosing protocols differed Patient populations differed Long-term orforglipron data is still developing A 5% to 10% reduction in body weight can still produce clinically meaningful improvements in blood pressure, insulin sensitivity, mobility, and metabolic health

Cosmetic procedures might be considered after weight stabilisation, though these are typically not available on the NHS and should be discussed with appropriate specialists